ANVS

Annovis Bio, Inc.

NYSE · Pharmaceutical Preparations · Inc. DE · CIK 0001477845

$1.79 -5.29% $61.3M

High Impact Filing (7/10)5 New Institutional Positions

Vol

Market Cap$61.3M

Cap SizeMicro Cap

Analyst ConsensusStrong Buy (88%)

Inst. Holders5 funds

Inst. Value$5.2M

Inst. Activity5 buys / 0 sells

Insider Activity2B / 0S

Insider Net $$1.5M

Reddit Sentiment57° Neutral

SEC Reports5

Press Releases2

Exchange NYSE·Sector Pharmaceutical Preparations·Inc. DE·CIK 0001477845·Prev Close $1.89

Recent Activity

Jun 5, 2026 short_volume

Short Volume: ANVS — 56.7% short (0.4M / 0.8M)

Short: 441,334 | Exempt: 3,800 | TRF Vol: 777,887 | Short Ratio: 56.7% | Off-exchange volume (dark p

May 20, 2026 SEC

Annovis Bio is raising approximately $13.8M in net proceeds through a dilutive offering of 7.9M shares and warrants, pri

424B5 — Impact 6/10

May 20, 2026 Insider

Hoffman Michael B bought 2,562 shares

Director @ $1.75 ($4.5K)

May 19, 2026 SEC

Annovis Bio filed a preliminary 424B5 for an underwritten offering of common stock and warrants, with no final pricing d

424B5 — Impact 7/10

May 15, 2026 SEC

Annovis Bio reported Q1 2026 results showing increased net loss per share ($0.63 vs $0.32) and cash burn, but highlighte

8-K — Impact 5/10

Apr 2, 2026 Insider

Hoffman Michael B bought 713,800 shares

Director @ $2.10 ($1.5M)

Inst.

VANGUARD GROUP INC — ADD

923,201 shares ($3.2M)

Inst.

TWO SIGMA INVESTMENTS, LP — NEW

551,837 shares ($1.9M)

Price Targets

$12.50 +606.2% upside Strong Buy

Current $1.77 Low $8.00 Median $12.50 High $17.00 2 analysts

$8.00 $17.00

Analyst Ratings

Strong Buy88% buy · 8 analysts

2Strong Buy

5Buy

1Hold

0Sell

0Strong Sell

Recent Analyst Actions

Date	Firm	Action	Rating
Apr 14, 2026	Canaccord Genuity	MAINTAIN	Buy → Buy

Earnings Estimates

Period	EPS Est.	Range	Growth	#
Current Q	$-0.48 ▼ -65.5%	$-0.48 — $-0.48	-50% YoY	1
Next Q	$-0.44 ▼ -57.1%	$-0.44 — $-0.44	-19% YoY	1
Current FY	$-1.80 ▼ -57.9%	$-1.80 — $-1.80	-29% YoY	1
Next FY	$-1.16 ▲ +14.7%	$-1.16 — $-1.16	36% YoY	1

Latest Reports

BEARISH 424B5 6/10

Annovis Bio is raising approximately $13.8M in net proceeds through a dilutive offering of 7.9M shares and warrants, pri

May 20, 2026

BEARISH 424B5 7/10

Annovis Bio filed a preliminary 424B5 for an underwritten offering of common stock and warrants, with no final pricing d

May 19, 2026

NEUTRAL Press 4/10

Annovis Bio has partnered with NeuroRPM to integrate an FDA-cleared AI-powered digital biomarker platform into its ongoi

Mar 19, 2026

Top Institutional Holders

Fund	Value	Move
VANGUARD GROUP INC	$3.2M	ADD
TWO SIGMA INVESTMENTS, LP	$1.9M	NEW
WELLS FARGO & COMPANY/MN	$49.5K	ADD
MORGAN STANLEY	$34.3K	ADD
BANK OF AMERICA CORP	$716.00	ADD

Recent Insider Trades

Date	Insider	Type	Value
May 20, 2026	Hoffman Michael	BUY	$4.5K
Apr 2, 2026	Hoffman Michael	BUY	$1.5M

Reddit Sentiment

57°

Neutral

Bearish Neutral Bullish

3 mentions 1 bullish 0 bearish

5 institutional holders with $5.2M total value (1,499,453 shares) as of 2025-Q4. Top holders: VANGUARD, TWO, WELLS. Net buying activity: 5 institutions added/increased vs 0 reduced.

Top Institutional Holders — 2025-Q4

#	Fund	Shares	Value	% of Tracked	Last Move
1	VANGUARD GROUP INC	923,201	$3.2M	61.6%	ADD +25.1%
2	TWO SIGMA INVESTMENTS, LP	551,837	$1.9M	36.8%	NEW
3	WELLS FARGO & COMPANY/MN	14,307	$49.5K	1.0%	ADD +46.8%
4	MORGAN STANLEY	9,901	$34.3K	0.7%	ADD +34.0%
5	BANK OF AMERICA CORP /DE/	207	$716.00	0.0%	ADD +42.8%

Recent Position Changes

Fund	Action	Prev Shares	Curr Shares	Change %	Value	Quarter
VANGUARD GROUP INC	ADD	738,003	923,201	+25.1%	$3.2M	2025-Q4
TWO SIGMA INVESTMENTS, LP	NEW	—	551,837	—	$1.9M	2025-Q4
WELLS FARGO & COMPANY/MN	ADD	9,746	14,307	+46.8%	$49.5K	2025-Q4
MORGAN STANLEY	ADD	7,389	9,901	+34.0%	$34.3K	2025-Q4
BANK OF AMERICA CORP /DE/	ADD	145	207	+42.8%	$716.00	2025-Q4
MORGAN STANLEY	TRIM	12,194	7,389	-39.4%	$15.3K	2025-Q3
UBS Group AG	NEAR_EXIT	26,317	633	-97.6%	$1.3K	2025-Q3
UBS Group AG	NEAR_EXIT	160,876	26,317	-83.6%	$57.1K	2025-Q2
TWO SIGMA INVESTMENTS, LP	EXIT	166,219	0	-100.0%	$0.00	2025-Q2
RENAISSANCE TECHNOLOGIES LLC	EXIT	21,800	0	-100.0%	$0.00	2025-Q2
VANGUARD GROUP INC	ADD	466,277	647,920	+39.0%	$971.9K	2025-Q1
TWO SIGMA INVESTMENTS, LP	DOUBLED	10,923	166,219	+1421.7%	$249.3K	2025-Q1
UBS Group AG	DOUBLED	48,736	160,876	+230.1%	$241.3K	2025-Q1
CITADEL ADVISORS LLC	NEAR_EXIT	535,707	125,300	-76.6%	$187.9K	2025-Q1
RENAISSANCE TECHNOLOGIES LLC	NEW	—	21,800	—	$32.7K	2025-Q1
MORGAN STANLEY	DOUBLED	1,300	10,189	+683.8%	$15.3K	2025-Q1
CITADEL ADVISORS LLC	ADD	385,092	535,707	+39.1%	$2.7M	2024-Q4
UBS Group AG	DOUBLED	1,847	48,736	+2538.7%	$245.1K	2024-Q4
MORGAN STANLEY	NEAR_EXIT	5,498	1,350	-75.4%	$10.9K	2024-Q3

1 unique insiders with 2 transactions. Net insider value: $1.5M ($1.5M bought, $0.00 sold).

Insider Transactions

Date	Insider	Title	Type	Shares	Price	Value
May 20, 2026	Hoffman Michael B	Director	BUY	2,562	$1.75	$4.5K
Apr 2, 2026	Hoffman Michael B	Director	BUY	713,800	$2.10	$1.5M

5 SEC filing reports analyzed. Sentiment: 0 bullish, 3 bearish, 2 mixed, 0 neutral. Avg impact: 6.0/10.

BEARISH 424B5 6/10

Annovis Bio is raising approximately $13.8M in net proceeds through a dilutive offering of 7.9M shar

May 20, 2026

BEARISH 424B5 7/10

Annovis Bio filed a preliminary 424B5 for an underwritten offering of common stock and warrants, wit

May 19, 2026

MIXED 8-K 5/10

Annovis Bio reported Q1 2026 results showing increased net loss per share ($0.63 vs $0.32) and cash

May 15, 2026

BEARISH PRESS-RELEASE 6/10

Annovis Bio reported Q1 2026 EPS of -$0.63, significantly below the -$0.35 consensus estimate, with

May 15, 2026

MIXED PRESS-RELEASE 6/10

Annovis Bio reported a wider-than-expected EPS loss of $-0.39 (vs $-0.36 est) with no revenue, but s

Apr 10, 2026

NEUTRAL 4/10

Annovis Bio has partnered with NeuroRPM to integrate an FDA-cleared AI-powered digital biomarker pla

Mar 19, 2026

MIXED 6/10

Annovis Bio reported financial results for 2025 alongside clinical progress updates, including initi

Mar 16, 2026

Current analyst consensus: Strong Buy (88% buy). Based on 8 analysts: 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$12.50 mean target +606.2% upside Strong Buy (1.50)

$8.00 Low $17.00 High

Metric	Value
Current Price	$1.77
Target Low	$8.00
Target Mean	$12.50
Target Median	$12.50
Target High	$17.00
# Analysts	2
Recommendation	Strong Buy (1.50)

Earnings Estimates & Revisions

Period	EPS Avg	EPS Low	EPS High	EPS Growth	30d Rev.	Up/Down	Rev. Avg	Rev. Growth	Analysts
Current Q 2026-06-30	$-0.48	$-0.48	$-0.48	-50.0%	-65.5%	0↑ 1↓	$0.0B	0.0%	1
Next Q 2026-09-30	$-0.44	$-0.44	$-0.44	-18.9%	-57.1%	0↑ 1↓	$0.0B	0.0%	1
Current FY 2026-12-31	$-1.80	$-1.80	$-1.80	-28.6%	-57.9%	0↑ 1↓	$0.0B	0.0%	1
Next FY 2027-12-31	$-1.16	$-1.16	$-1.16	35.6%	+14.7%	1↑ 0↓	$0.0B	0.0%	1

Current Quarter EPS Revision History

Timepoint	EPS Estimate	Change
Current	$-0.480
7d ago	$-0.290	-0.190
30d ago	$-0.290	-0.190
60d ago	$-0.310	-0.170
90d ago	$-0.280	-0.200

1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.

Individual Analyst Actions

Date	Analyst Firm	Action	Previous Rating	New Rating
Apr 14, 2026	Canaccord Genuity	MAINTAIN	Buy	Buy

Monthly Consensus History

Period	Strong Buy	Buy	Hold	Buy %
Jun 1, 2026	2	5	1	88%
May 1, 2026	2	7	1	90%
Apr 1, 2026	2	7	1	90%
Mar 1, 2026	2	7	1	90%
Feb 1, 2026	2	7	1	90%
Jan 1, 2026	2	7	1	90%

Strong BuyBuyHoldSellStrong Sell

∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

57°

Neutral

Bearish Neutral Bullish

3 mentions 1 bullish 0 bearish 2 time periods

Reddit Sentiment History

Date	Mentions	Sentiment	Bullish	Bearish	Threads
May 6, 2026	2	58° Warm	1	0	2
May 6, 2026	1	44° Neutral	0	0	1

Recent Reddit Threads

r/pennystocks Bullish 1mo ago

GANX Phase 2 in Q3. ANVS has going concern language. AVXL has $131M cash but CHMP rejection. Spread between them is wide. Anyone else tracking these?

▲ 1 💬 1 ⚡ 0.3

r/pennystocks Neutral 1mo ago

Parkinson's Watchlist: Risk breakdown: GANX = early data, high dilution risk. ANVS = late-stage assets, balance sheet stress. AVXL = financial cushion, regulatory uncertainty. Pick your poison.

▲ 1 💬 1 ⚡ 0.5

Jun 5, 2026

short_volume

Short Volume: ANVS — 56.7% short (0.4M / 0.8M)

Short: 441,334 | Exempt: 3,800 | TRF Vol: 777,887 | Short Ratio: 56.7% | Off-exchange volume (dark pool + OTC)

Jun 4, 2026

short_volume

Short Volume: ANVS — 66.4% short (0.7M / 1.1M)

Short: 737,392 | Exempt: 4,485 | TRF Vol: 1,111,145 | Short Ratio: 66.4% | Off-exchange volume (dark pool + OTC)

Jun 2, 2026

short_volume

Short Volume: ANVS — 69.0% short (0.5M / 0.8M)

Short: 524,007 | Exempt: 915 | TRF Vol: 759,795 | Short Ratio: 69.0% | Off-exchange volume (dark pool + OTC)

May 21, 2026

short_volume

Short Volume: ANVS — 55.4% short (0.3M / 0.6M)

Short: 306,113 | Exempt: 1,112 | TRF Vol: 552,484 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)

May 19, 2026

offering

Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants

<p>MALVERN, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnolog

May 15, 2026

earnings

Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results

<p>MALVERN, Pa., May 15, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnolog

May 13, 2026

earnings_calendar

ANVS Q1 2026 Earnings Scheduled — 2026-05-13

May 11, 2026

earnings_calendar

ANVS Q1 2026 Earnings Scheduled — 2026-05-11

Apr 23, 2026

short_volume

Short Volume: ANVS — 65.4% short (0.4M / 0.6M)

Short: 422,868 | Exempt: 440 | TRF Vol: 646,953 | Short Ratio: 65.4% | Off-exchange volume (dark pool + OTC)

Apr 20, 2026

short_volume

Short Volume: ANVS — 63.9% short (0.4M / 0.6M)

Short: 413,916 | Exempt: 1,150 | TRF Vol: 647,769 | Short Ratio: 63.9% | Off-exchange volume (dark pool + OTC)

Apr 17, 2026

short_volume

Short Volume: ANVS — 61.5% short (0.4M / 0.7M)

Short: 445,994 | Exempt: 8,623 | TRF Vol: 725,097 | Short Ratio: 61.5% | Off-exchange volume (dark pool + OTC)

Apr 15, 2026

short_volume

Short Volume: ANVS — 71.1% short (0.4M / 0.6M)

Short: 424,807 | Exempt: 657 | TRF Vol: 597,647 | Short Ratio: 71.1% | Off-exchange volume (dark pool + OTC)

Apr 14, 2026

short_volume

Short Volume: ANVS — 68.8% short (0.6M / 0.8M)

Short: 579,065 | Exempt: 9,591 | TRF Vol: 841,460 | Short Ratio: 68.8% | Off-exchange volume (dark pool + OTC)

Apr 13, 2026

short_volume

Short Volume: ANVS — 75.1% short (1.0M / 1.4M)

Short: 1,027,608 | Exempt: 4,159 | TRF Vol: 1,367,811 | Short Ratio: 75.1% | Off-exchange volume (dark pool + OTC)

Apr 10, 2026

earnings

Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission

<p>MALVERN, Pa., April 10, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnol